A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/127 (2006.01) A61K 31/445 (2006.01) A61K 38/16 (2006.01) A61K 39/00 (2006.01) A61K 39/395 (2006.01) A61P 31/12 (2006.01)
Patent
CA 2659858
One can treat a viral infection such as hepatitis B (HBV), hepatitis C (HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the endoplasmic reticulum (ER) membrane. Two exemplary liposome formulations are DOPE/CHEMS (DC liposomes) and DOPE/CHEMS/PEG-PE (DCPP liposomes). DC and DCPP liposomes can optimize the intracellular delivery of N-butyl deoxynojirimycin (NB-DNJ), and consequently increase the in vivo activity of this iminosugar several orders of magnitude, and could be used in combination with other therapeutic agents such as interferon and/or ribavirin. The optimized release of NB-DNJ directly into the ER can be also applied for the treatment of other viruses, for which NB-DNJ is known to be an effective antiviral, such as human immunodeficiency virus (HIV).
Il est possible de traiter une infection virale du type hépatite B (HBV), hépatite C (HCV), et virus de la diarrhée virale bovine (BVDV) par l'apport de liposomes sensibles au pH directement dans la membrane du réticulum endoplasmique (ER). Deux formulations liposomales (exemples) sont DOPE/CHEMS ( liposomes DC) et DOPE/CHEMS/PEG-PE (liposomes DCPP). Ces deux types de liposomes permettent d'optimiser l'apport intracellulaire de N-butyl désoxynojirimycine (NB-DNJ) et d'augmenter ainsi l'activité in vivo de cet iminosucre de plusieurs ordres de grandeur, en offrant la possibilité d'une utilisation en combinaison avec d'autres agents thérapeutiques comme l'interféron et/ou la ribavirine. La libération optimisée de NB-DNJ directement dans l'ER peut aussi être appliquée pour le traitement d'autres virus, pour lesquels on sait que NB-DNJ est un antiviral efficace, comme le VIH.
Dwek Raymond A.
Nichita-Branza Norica
Petrescu Stefana
Pollock Stephanie
Rudd Pauline
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
United Therapeutics Corporation
University Of Oxford
LandOfFree
Liposome treatment of viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liposome treatment of viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposome treatment of viral infections will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1582657